Skip to main content

Table 3 Drug list for ATP-TCA with manufacturer, given with the 100% test drug concentration (TDC) used in the assay, and the number of tumors tested.

From: Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC)

Drug or combination

Manufacturer

TDC (μM)

Number tested

Docetaxel

Sanofi-Aventis

3.00

43

Cisplatin

Bristol-Myers-Squibb

10.00

41

Gemcitabine

Eli Lilly

40.04

39

Cisplatin with Gemcitabine

As single agents

As single agents

38

Docetaxel with Cisplatin

As single agents

As single agents

22

Docetaxel with Gemcitabine

As single agents

As single agents

21

  1. Some tumors had too few cells for all agents/combinations to be tested.